132 related articles for article (PubMed ID: 36254078)
1. Data-independent acquisition-based quantitative proteomic analysis of m.3243A>G MELAS reveals novel potential pathogenesis and therapeutic targets.
Chang X; Yin Z; Zhang W; Shi J; Pu C; Shi Q; Wang J; Zhang J; Yan L; Yang W; Guo J
Medicine (Baltimore); 2022 Oct; 101(41):e30938. PubMed ID: 36254078
[TBL] [Abstract][Full Text] [Related]
2. One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.
Esterhuizen K; Lindeque JZ; Mason S; van der Westhuizen FH; Rodenburg RJ; de Laat P; Smeitink JAM; Janssen MCH; Louw R
Metabolomics; 2021 Jan; 17(1):10. PubMed ID: 33438095
[TBL] [Abstract][Full Text] [Related]
3. The MELAS mutation m.3243A>G promotes reactivation of fetal cardiac genes and an epithelial-mesenchymal transition-like program via dysregulation of miRNAs.
Meseguer S; Panadero J; Navarro-González C; Villarroya M; Boutoual R; Comi GP; Armengod ME
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3022-3037. PubMed ID: 29928977
[TBL] [Abstract][Full Text] [Related]
4. Independent origin for m.3243A>G mitochondrial mutation in three Venezuelan cases of MELAS syndrome.
Florez I; Pirrone I; Casique L; Domínguez CL; Mahfoud A; Rodríguez T; Rodríguez D; De Lucca M; Ramírez JL
Clin Biochem; 2022; 109-110():98-101. PubMed ID: 36130631
[TBL] [Abstract][Full Text] [Related]
5. Impediments to Heart Transplantation in Adults With MELAS
Di Toro A; Urtis M; Narula N; Giuliani L; Grasso M; Pasotti M; Pellegrini C; Serio A; Pilotto A; Antoniazzi E; Rampino T; Magrassi L; Valentini A; Cavallini A; Scelsi L; Ghio S; Abelli M; Olivotto I; Porcu M; Gavazzi A; Kodama T; Arbustini E
J Am Coll Cardiol; 2022 Oct; 80(15):1431-1443. PubMed ID: 36202533
[TBL] [Abstract][Full Text] [Related]
6. Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome.
Chakrabarty S; Govindaraj P; Sankaran BP; Nagappa M; Kabekkodu SP; Jayaram P; Mallya S; Deepha S; Ponmalar JNJ; Arivinda HR; Meena AK; Jha RK; Sinha S; Gayathri N; Taly AB; Thangaraj K; Satyamoorthy K
J Neurol; 2021 Jun; 268(6):2192-2207. PubMed ID: 33484326
[TBL] [Abstract][Full Text] [Related]
7. A case of exacerbated encephalopathy with stroke-like episodes and lactic acidosis triggered by metformin in a patient with MELAS.
Shin HJ; Na JH; Lee YM
Neurol Sci; 2024 May; 45(5):2337-2339. PubMed ID: 38265537
[TBL] [Abstract][Full Text] [Related]
8. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.
El-Hattab AW; Adesina AM; Jones J; Scaglia F
Mol Genet Metab; 2015; 116(1-2):4-12. PubMed ID: 26095523
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone and Deoxyribonucleoside Combination Treatment Increases Mitochondrial Respiratory Capacity in m.3243A>G MELAS Cybrid Cells.
Burgin HJ; Lopez Sanchez MIG; Smith CM; Trounce IA; McKenzie M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244971
[TBL] [Abstract][Full Text] [Related]
10. Adult-onset Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke (MELAS)-like Encephalopathy Diagnosed Based on the Complete Sequencing of Mitochondrial DNA Extracted from Biopsied Muscle without any Myopathic Changes.
Mukai M; Nagata E; Mizuma A; Yamano M; Sugaya K; Nishino I; Goto YI; Takizawa S
Intern Med; 2017; 56(1):95-99. PubMed ID: 28050007
[TBL] [Abstract][Full Text] [Related]
11. Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS.
Liufu T; Zhao X; Yu M; Xie Z; Meng L; Lv H; Zhang W; Yuan Y; Xing G; Deng J; Wang Z
FASEB J; 2024 Jun; 38(12):e23742. PubMed ID: 38865203
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes due to m.3243A > G mutation in a 76-year-old woman.
Ueki K; Wakisaka Y; Nakamura K; Shono Y; Wada S; Yoshikawa Y; Matsukuma Y; Uchiumi T; Kang D; Kitazono T; Ago T
J Neurol Sci; 2020 May; 412():116791. PubMed ID: 32224343
[No Abstract] [Full Text] [Related]
13. Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: contribution to understanding mitochondrial DNA segregation during human embryofetal development.
Bouchet C; Steffann J; Corcos J; Monnot S; Paquis V; Rötig A; Lebon S; Levy P; Royer G; Giurgea I; Gigarel N; Benachi A; Dumez Y; Munnich A; Bonnefont JP
J Med Genet; 2006 Oct; 43(10):788-92. PubMed ID: 16690729
[TBL] [Abstract][Full Text] [Related]
14. Activation of the mitochondrial protein quality control system and actin cytoskeletal alterations in cells harbouring the MELAS mitochondrial DNA mutation.
Felk S; Ohrt S; Kussmaul L; Storch A; Gillardon F
J Neurol Sci; 2010 Aug; 295(1-2):46-52. PubMed ID: 20570288
[TBL] [Abstract][Full Text] [Related]
15. Integrated proteomic and metabolomic analyses of the mitochondrial neurodegenerative disease MELAS.
Li H; Uittenbogaard M; Navarro R; Ahmed M; Gropman A; Chiaramello A; Hao L
Mol Omics; 2022 Mar; 18(3):196-205. PubMed ID: 34982085
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging characteristics in mitochondrial encephalopathies associated with the m.3243A>G MTTL1 mutation.
Tschampa HJ; Urbach H; Greschus S; Kunz WS; Kornblum C
J Neurol; 2013 Apr; 260(4):1071-80. PubMed ID: 23196335
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) due to a m.10158T>C ND3 Mutation with a Normal Muscle Biopsy.
Mukai M; Nagata E
Intern Med; 2017 Oct; 56(19):2695. PubMed ID: 28883258
[No Abstract] [Full Text] [Related]
18. Fulminant cerebral venous thrombosis associated with the m.3243A>G MELAS mutation: A new guise for an old disease.
Nikolaus M; Tietze A; Schweizer L; Kaindl AM; Stenzel W; Schuelke M; Knierim E
Brain Dev; 2019 Nov; 41(10):901-904. PubMed ID: 31345444
[TBL] [Abstract][Full Text] [Related]
19. Modeling Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome Using Patient-Derived Induced Neurons Generated by Direct Reprogramming.
Povea-Cabello S; Villanueva-Paz M; Villalón-García I; Talaverón-Rey M; Álvarez-Cordoba M; Suárez-Rivero JM; Montes MÁ; Rodríguez-Moreno A; Andrade-Talavera Y; Armengol JA; Sánchez-Alcázar JA
Cell Reprogram; 2022 Oct; 24(5):294-303. PubMed ID: 35802497
[TBL] [Abstract][Full Text] [Related]
20. A urinary biosignature for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS).
Esterhuizen K; Lindeque JZ; Mason S; van der Westhuizen FH; Suomalainen A; Hakonen AH; Carroll CJ; Rodenburg RJ; de Laat PB; Janssen MCH; Smeitink JAM; Louw R
Mitochondrion; 2019 Mar; 45():38-45. PubMed ID: 29471047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
